<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392691</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 37/05</org_study_id>
    <secondary_id>SWS-SAKK-37/05</secondary_id>
    <secondary_id>EU-20648</secondary_id>
    <secondary_id>SPRI-SWS-SAKK-37/05</secondary_id>
    <secondary_id>CDR0000511915</secondary_id>
    <nct_id>NCT00392691</nct_id>
  </id_info>
  <brief_title>Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment</brief_title>
  <official_title>Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell&#xD;
      transplant helps stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Also, monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan&#xD;
      and rituximab, can find cancer cells and carry cancer-killing substances to them without&#xD;
      harming normal cells. Chemotherapy and monoclonal antibody therapy also prepares the&#xD;
      patient's bone marrow for the stem cell transplant. Giving colony-stimulating factors, such&#xD;
      as G-CSF, and vinorelbine helps stem cells move from the bone marrow to the blood so they can&#xD;
      be collected and stored. The stem cells are returned to the patient to replace the&#xD;
      blood-forming cells that were destroyed by the chemotherapy and monoclonal antibody therapy.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of melphalan when&#xD;
      given together with yttrium Y 90 ibritumomab tiuxetan and rituximab followed by autologous&#xD;
      stem cell transplant in treating older patients with non-Hodgkin's lymphoma that has relapsed&#xD;
      or not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of high-dose melphalan when given together with&#xD;
           yttrium Y 90 ibritumomab tiuxetan and rituximab as a conditioning regimen followed by&#xD;
           vinorelbine ditartrate- and filgrastim (G-CSF)-mobilized autologous stem cell&#xD;
           transplantation in elderly patients with relapsed or refractory CD20-positive&#xD;
           non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Evaluate the feasibility and safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the feasibility of stem cell mobilization with vinorelbine ditartrate in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of high-dose melphalan.&#xD;
&#xD;
        -  Stem cell harvest and mobilization: Patients receive vinorelbine ditartrate IV on day&#xD;
           -36 and filgrastim (G-CSF) subcutaneously (SC) twice daily on days -33 to -29. Patients&#xD;
           undergo peripheral blood stem cell harvest on days -29 to -26.&#xD;
&#xD;
        -  Radioimmunotherapy: Patients receive rituximab IV. Within 4 hours after completion of&#xD;
           rituximab, patients receive indium In 111 ibritumomab tiuxetan (imaging dose) IV over 10&#xD;
           minutes on day -25. Patients undergo assessment of biodistribution, imaging, and&#xD;
           dosimetry on days -25, -22, and optionally on day -20. Patients with acceptable&#xD;
           biodistribution of indium In 111 ibritumomab tiuxetan receive rituximab IV followed by&#xD;
           yttrium Y 90 ibritumomab tiuxetan (therapeutic dose) IV over 10 minutes on day -18.&#xD;
&#xD;
        -  High-dose chemotherapy: Patients receive high-dose melphalan IV on day -1. Cohorts of&#xD;
           3-6 patients receive escalating doses of high-dose melphalan until the maximum tolerated&#xD;
           dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
           patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Autologous stem cell transplantation (ASCT): Patients undergo ASCT on day 0. Patients&#xD;
           receive G-CSF SC beginning on day 5 and continuing until blood counts recover.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 100 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity of high-dose melphalan in combination with yttrium Y 90 ibritumomab tiuxetan</measure>
    <time_frame>within 8 weeks after application of melphalan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>100 days (+/- 5 days) after reinfusion of stem cells</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event occurrence up to 100 days after transplantation</measure>
    <time_frame>up to 100 days after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission 100 days after transplantation</measure>
    <time_frame>100 days after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibritumomab tiuxetan</intervention_name>
    <description>185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients &gt; 80kg) for imaging.</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>ZEVALIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>250 mg/m2</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Dose level 1: 100 mg/m2&#xD;
Dose level 2: 140 mg/m2&#xD;
Dose level 3: 170 mg/m2&#xD;
Dose level 4: 200 mg/m2</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate / G-CSF</intervention_name>
    <description>on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell harvesting and transplantation</intervention_name>
    <description>Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.&#xD;
Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils &gt; 0.5x109/l for at least 2 consecutive days.</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-Hodgkin's lymphoma of any type&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  Achieved partial or complete response to salvage treatment for relapse or refractory&#xD;
             disease within the past 10 weeks&#xD;
&#xD;
          -  Must have an indication for autologous stem cell transplantation&#xD;
&#xD;
          -  Bone marrow infiltration &lt; 25%&#xD;
&#xD;
          -  No evidence of CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times ULN&#xD;
&#xD;
          -  AST ≤ 2 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  No clinically significant cardiac disease, including any of the following:&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Significant arrhythmia&#xD;
&#xD;
               -  Myocardial infarction within the past 3 months&#xD;
&#xD;
          -  LVEF &gt; 50%&#xD;
&#xD;
          -  No clinically significant urinary tract obstruction&#xD;
&#xD;
          -  No clinically significant pulmonary disease&#xD;
&#xD;
          -  No serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             adequately treated in situ cervical cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 30 days since prior participation in another clinical trial&#xD;
&#xD;
          -  No prior stem cell transplantation&#xD;
&#xD;
          -  No prior radiolabeled antibodies, including for induction of disease remission&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Voegeli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Liestal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Ghielmini, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>IOSI, Ospedale San Giovanni</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelika Bischof Delaloye, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Faculté de biologie et de médecine de l' Université de Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Bern</city>
        <zip>CH-3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M. Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Hematol Oncol. 2017 Dec;35(4):576-583. doi: 10.1002/hon.2348. Epub 2016 Sep 28.</citation>
    <PMID>27677906</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

